Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Brii Biosciences Limited ( (HK:2137) ) is now available.
Brii Biosciences Limited announced a supplemental update to its 2024 Annual Report, detailing changes in the use of net proceeds from its global offering. The company has revised its allocation of funds, particularly for its hepatitis B and HIV programs, to better support ongoing clinical trials and regulatory preparations. This strategic reallocation aims to enhance the company’s operational efficiency and strengthen its position in the biotechnology industry.
The most recent analyst rating on (HK:2137) stock is a Hold with a HK$2.00 price target. To see the full list of analyst forecasts on Brii Biosciences Limited stock, see the HK:2137 Stock Forecast page.
More about Brii Biosciences Limited
Brii Biosciences Limited is a biotechnology company incorporated in the Cayman Islands, focusing on developing innovative therapies for infectious diseases such as hepatitis B and HIV. The company is listed on the Hong Kong Stock Exchange and is engaged in clinical trials and preparation for regulatory filings to advance its therapeutic programs.
Average Trading Volume: 6,354,816
Technical Sentiment Signal: Buy
Current Market Cap: HK$1.42B
For detailed information about 2137 stock, go to TipRanks’ Stock Analysis page.